Floatz logo

L-CYSTEINE, L-CYSTEINYL-L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-LYSYLGLYCYL-L-PROLYL-L-.ALPHA.-ASPARTYL-, CYCLIC (1->9)-DISULFIDE

Acinar Cell Adenocarcinoma of the Pancreas

City of Hope Medical Centerprotein_peptidePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Acinar Cell Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Yale University
Phase 2BBB
Eloxatin
Yale University
Phase 2BBB
Irinotecan
Artios Pharma Ltd
Phase 2BB
Metformin
Case Comprehensive Cancer Center
Phase 2BB
Carboplatin
National Cancer Institute (NCI)
Phase 2B

View all 34 →

Same molecule, other indications

L-CYSTEINE, L-CYSTEINYL-L-ARGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-LYSYLGLYCYL-L-PROLYL-L-.ALPHA.-ASPARTYL-, CYCLIC (1->9)-DISULFIDE is also rated in:

pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
breast cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →